Currently Viewing:
Evidence-Based Oncology Patient-Centered Oncology Care: Real-World Perspectives 2013
The Angelina Effect: Rising Interest in Genetic Testing Creates Opportunities for Patients-and Profit
Ellen T. Matloff, MS
Currently Reading
Faculty Index
Will Shifts in Oncology Outpatient Points of Care Lead to More Profits or Savings?
Peter B. Bach, MD, MAPP
Care Reflects Patient Choice, but Having the Data Reflect 'Consumerism' Is Another Matter
Cliff Goodman, PhD; Amy Berman, BS, RN; Dennis Scanlon, PhD; and Manasi A. Tirodkar, PhD, MS,
When Making Decisions in Cancer Care, Patients Want to Know: How Will I Feel?
Ethan Basch, MD
Cancer Patients Need Better Information, and Payers Should Demand They Receive It
Cliff Goodman, PhD; A. Mark Fendrick, MD; John L. Fox, MD, MHA; and Ira M. Klein, MD, MBA, FACP
Measures That Improve Quality Must Be Nimble if Imperfect, UnitedHealthcare's Newcomer Explains
Lee N. Newcomer, MD, MHA
With Data, Access and Sharing Are Keys to Improving Quality
Lee N. Newcomer, MD, MHA; Phyllis Torda; Dennis Scanlon, PhD; Ira M. Klein, MD, MBA, FACP
Can Clinical Pathways Change the 'Culture' in Cancer Care?
Bruce A. Feinberg, DO
Payer Perspectives in Genetic Counseling
Karen Lewis, MS, MM, CGC
Grappling With the Fallout of Genetic Testing, in Oncology and Beyond
Ira M. Klein, MD, MBA, FACP; Jan Berger, MD, MJ; Michael A. Kolodziej, MD
The Present-and Future-of Genetic Profiling in Oncology
Jerry Conway
Next-Generation Sequencing in Oncology: Are We Ready for Prime Time?
Lee N. Newcomer, MD, MHA; Michael A. Kolodziej, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP
Putting the 'Economics' Back Into Health Economics Outcomes Research
Scott D. Ramsey, MD, PhD
Value-Based Pricing: The Role of Outcomes Data in Pricing Models
Michael E. Chernew, PhD; Cliff Goodman, PhD; Jeffrey D. Dunn, PharmD, MBA; Kirby Eng, RPh
Redefining the Role of Industry in Contemporary Healthcare
John L. Fox, MD, MHA; Bo Gamble; and Cliff Goodman, PhD

Faculty Index

List of faculty who participated in PCOC 2013
Peter B. Bach, MD, MAPP
Director, Center for Health
Policy and Outcomes
Memorial Sloan-Kettering Cancer Center
Dr Bach’s main research interests cover healthcare policy, particularly as it relatesto Medicare, racial disparities in cancer care quality, and lung cancer epidemiology. A former senior adviser to the administrator of the Centers for Medicare & Medicaid Services (CMS), he serves on several national committees, including the Institute of Medicine’s National Cancer Policy Forum and the Committee on Performance Measurement of the National Committee on Quality Assurance. He chairs the Technical Expert Panel that is developing measures of cancer care quality for CMS.

See pages SP70, SP71

Ethan Basch, MD
Director of Cancer Outcomes Research
University of North Carolina Chapel Hill
Dr Basch is a practicing oncologist and director of the Cancer Outcomes Research Program at the University of North Carolina in Chapel Hill. His research focuses on patient-reported outcomes in clinical trials, comparative effectiveness, and quality-of care assessments. He is a member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), a member of the Board of Scientific Advisors of the National Cancer Institute, chairs the Health Outcomes Committee of the Alliance for Clinical Trials in Oncology, and serves on the Board of Directors of the International Society for Quality of Life Research.
See page SP75, SP76

Jan Berger, MD, MJ
President, CEO
Health Intelligence Partners
Dr Berger founded Health Intelligence Partners 6 years ago as a healthcare consultancy that blends more than 25 years of both business and clinical experience. Prior to founding Health Intelligence Partners, Dr Berger served as senior vice president and chief clinical officer for CVS Caremark. She presently sits on the boards of Care Core National (committees: finance, compensation, search, mergers & acquisitions, and strategic directions), Meals to Heal, The University of Arizona School of Pharmacy, RxAnte, and Midwest Business Group on Health. Dr Berger is the editor-in-chief of The American Journal of Pharmacy Benefits.

See pages SP87

Amy Berman, BS, RN
Senior Program Officer
The John A. Hartford Foundation
Berman is a senior program officer with the John A. Hartford Foundation. She heads the Foundation’s development and dissemination of innovative, costeffective models of care that improve health outcomes for older adults. She works to advance palliative care and to reduce avoidable readmissions. Berman also works on collaborations with federal partners, including the Centers for Medicare & Medicaid Innovation, the Office of the National Coordinator for Health Information Technology, and the Administration for Community Living. She has openly shared her experiences living with stage IV breast cancer, presenting to the Institute on Medicine.

See pages SP69, SP70, SP71, SP75, SP85, SP88
Michael E. Chernew, PhD
The American Journal of Managed Care
Dr Chernew is the Leonard D. Schaeffer Professor of Health Care Policy at Harvard Medical School. His research activities focus on several areas, most notably the causes and consequences of growth in healthcare expenditures, geographic variation in medical spending, and use of Value-Based Insurance Design. Dr Chernew is vice chair of the Medicare Payment Advisory Commission, an independent agency established to advise the US Congress on issues affecting the Medicare program. He is also a member of the Congressional Budget Office’s Panel of Health Advisors. In 2010, Dr Chernew was elected to the Institute of Medicine of the National Academy of Sciences; he served on the Committee on the Determination of Essential Health Benefits.
See pages SP91, SP92

Jerry Conway
VP of Reimbursement & Payer Strategy
Foundation Medicine, Inc
Conway joined Foundation Medicine Inc in May 2012 with over 22 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces. His experience includes payer contracting and reimbursement in a wide range of business environments, including Fortune 500 and start-up companies. He has previously worked for Metamark Genetics Inc, a national provider of cancer prognostic tests and services, as vice president of reimbursement and payer contracting.
See pages SP88, SP90

Jeffrey D. Dunn, PharmD, MBA
Senior Vice President
VRx Pharmacy
Dr Dunn is senior vice president at VRx, an integrated pharmacy services management company. VRx incorporates PBM functions, pharmacy & therapeutics (P&T)/formulary management, medication therapy management (MTM)/integrated care management (ICM), and government functions for commercial and Medicare Part D employer groups and health plans. Dr Dunn is a board member at VRx and oversees all clinical responsibilities. He manages the P&T process and formularies for commercial and Medicare Part D, as well as all MTM/ICM activities. He is an active member of the Academy of Managed Care Pharmacy, the American Society of Health-System Pharmacists, and the Utah Pharmaceutical Association. He is a reviewer for the Journal of Managed Care Pharmacy and Managed Care Interface, an editor for the International Scholarly Research Network and Oncology Business News, and sits on the editorial board of The American Journal of Managed Care.
See pages SP91, SP92
Kirby Eng, RPh
Director, Oncology Medical Pharmacy Management
CVS Caremark
Eng is responsible for the development and implementation of oncology specialty drug management strategies for CVS Caremark health plan and employer clients. He has more than 16 years of broad oncology experience in specialty pharmacy, manufacturing, sales and market strategic planning, group purchasing, oncology drug distribution, and provider network management. Before CVS Caremark, he held positions with CuraScript Specialty Pharmacy, US Oncology, Oncology Therapeutics Network (McKesson Specialty), Sicor (Teva), and Eli Lilly and Co. He has been an active participant on National Comprehensive Cancer Network task forces involving oral chemotherapy, specialty pharmacy, and risk evaluation and mitigation strategies.
See pages SP91, SP92
Bruce A. Feinberg, DO
Vice President and Chief Medical Officer
Cardinal Health Specialty Solutions, Clinical Pathways
Dr Feinberg is a leading oncologist recognized for his expertise in oncology and the business of specialty healthcare. He serves as vice president and chief medical officer for the Clinical Pathways business of Cardinal Health Specialty Solutions. Prior to joining the Cardinal Health team, Dr Feinberg was instrumental in establishing Georgia Cancer Specialists (GCS), the largest and first integrated oncologic specialty practice in the southeast. As CEO and president of GCS, he expanded community access to oncology care by bringing the latest cancer treatments, technologies, and clinical trials closer to the patient. In 2012, Specialty Solutions launched PathWareTM Decision Transaction Solutions, a software technology that Dr Feinberg was instrumental in designing, to improve the work flow process for payers and physicians. He is the author of the best-selling Breast Cancer Answers and its follow-up book, Colon Cancer Answers.

See page SP85, SP86
A. Mark Fendrick, MD
Professor, Division of General Medicine, Department of Internal Medicine and Department of Health Management and Policy
University of Michigan
Dr Fendrick is a professor of internal medicine in the School of Medicine and a professor of health management and policy in the School of Public Health at the University of Michigan. He currently directs the Center for Value-Based Insurance Design at the University of Michigan, the leading advocate for development, implementation, and evaluation of innovative health benefit plans. Dr Fendrick’s research focuses on the clinical and economic assessment of medical interventions, with special attention to how technological innovation influences clinical practice, benefit design, and healthcare systems. He is the co-editor-in-chief of The American Journal of Managed Care.
See pages SP76
John L. Fox, MD, MHA
Senior Medical Director, and Associate Vice President,
Medical Affairs
Priority Health
Dr Fox is the senior medical director and associate vice president of medical affairs for Priority Health, a provider-sponsored health plan with 640,000 members. He is responsible for technology assessment (medical and pharmaceutical) and utilization and case management. He is engaged in new program development including physician profiling, pay-for-performance programs, integrated specialty pharmacy, and value-based benefit designs. He is currently involved in development of payment reform strategies, including the oncology medical home.
See pages SP76, SP88, SP90, SP92

Bo Gamble
Director of Strategic Practice Initiatives
Community Oncology Alliance
Gamble joined Community Oncology Alliance in May 2011 as the director of strategic practice initiatives. He has a diverse range of cancer and other healthcare experience at the national and
local levels. His experience includes serving 13 years as administrator of a multiphysician, multi-location oncology practice in eastern North Carolina. In his other 17 years of healthcare experience, he has served as an independent consultant for hospital patient accounting and IT implementation
projects, national director of client support for a healthcare software company, and business office manager for a 300+ bed hospital. He has served as the president and legislative chairperson
for the North Carolina oncology practice management society, a member of the COA Board of Directors, and the co-chair of the national COA Administrators’ Network.

See page SP92
Cliff Goodman, PhD
Senior Vice President & Principal
The Lewin Group
Dr Goodman is senior vice president and principal at The Lewin Group, a healthcare policy and human services consulting firm based in Falls Church, Virginia. He has 30 years of experience in such areas as health technology assessment, evidence-based healthcare, comparative effectiveness research, health economics, and studies pertaining to healthcare innovations, regulation, and payment. He directs studies and projects for an international range of government agencies; pharmaceutical, biotechnology, and medical device companies; healthcare provider institutions; and professional, industry, and patient advocacy groups. Dr Goodman served as chair of the Medicare Evidence Development & Coverage Advisory Committee for the Centers for Medicare & Medicaid Services (2009-2012). He is president of the professional society, Health Technology Assessment International, and is a fellow of the American Institute for Medical and Biological Engineering.
See pages SP71, SP75, SP76, SP91, SP92

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!